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To investigate molecular therapeutic targets in cancer metastasis,
comparative proteomic analysis was performed using the isogenic
colorectal cancer cell lines SW480 and SW620. Two potential
metastasis related molecular targets were identiﬁed: fatty acid
synthase and histone H4. Subsequently, metastatic SW620 cells
were treated with six anti-cancerous components and suppressive
effects were observed in target protein expression. Through
comprehensive proteomic analysis, three of the tested compounds,
oxaliplatin, ginsenoside 20(S)-Rg3 and curcumin, were determined
to have a suppressive effect on fatty acid synthase and histone H4
expression [1]. The current article contains one table exhibiting a
list of proteins differentially expressed in metastatic SW620 cell
lines compared to the primary SW480 cell line (Supplementary
Table 1). Additionally, six tables demonstrate proteome changes in
SW620 resulting from the treatment of three chemotherapeutics
and three natural components (Supplementary Tables 1–7). The
anti-metastatic components revealed by the current proteomic
analysis represent promising chemotherapeutic candidates for the
treatment of colorectal adenocarcinoma.
& 2014 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).vier Inc. This is an open access article under the CC BY license
wang).
J.-G. Lee et al. / Data in Brief 1 (2014) 73–7574Fig. 1. ASpeciﬁcations tableSubject area Biochemistry
More speciﬁc subject
areaProteomicsType of data Tables
How data was
acquiredUsing a linear ion-trap mass spectrometry combined with nano-UPLC (Thermo Scientiﬁc LTQ/
Orbitrap-XLþWaters Nanoacquity UPLC system)Data format Data were ﬁltered by XCorr score after SEQUEST search, compiled using Scaffold™ and statistically
analyzed by Power Law Global Error Model (PLGEM).Experimental factors SW620 cells were treated with oxaliplatin, sorafenib, 5-ﬂuorouracil, ginsenoside 20(S)-Rg3,
curcumin, and luteolin (see Supplementary Tables)Experimental
featuresProteomics data from SW480 and SW620 with various drug treatmentConsent N/a
Data source location Data are present with this articleValue of the data
 The presented list of differentially expressed proteins from SW620 and SW480 could represent putative molecular targets
involved in colorectal cancer metastasis.
 Drug treatment of the metastatic SW620 cell line provides comprehensive information about cellular response to the
tested drugs.
 Current experimental datasets may provide insight as to whether combinational treatment might allow a better therapeutic
effect via synergistic activity.1. Experimental design, materials and methods
1.1. Cell culture and drug treatment
Fig. 1 shows a workﬂow of proteomic analysis for characterization of metastatic cancer biomarkers.
Cells were cultured in a Dulbecco's modiﬁed eagle medium (DMEM, Gibco BRL Life Technologies,
Grand Island, NY, USA) containing 10% fetal bovine serum (FBS), 50 units/mL of penicillin G and
50 mcg/mL of streptomycin which were purchased from Gibco BRL Life Technologies (Grand Island,
NY, USA). Cells were maintained at 37 1C under humidiﬁed 95% air and 5% CO2 and grown to
conﬂuence in culture dishes (150 mm diameter) over 2 or 3 days and then trypsinized and used for
the experiments. Stock solutions of tested drugs were diluted to the desired concentration and were
administered in the presence of DMEM with reduced serum (0.5% FBS). Three chemotherapeutics,
namely oxaliplatin, sorafenib and 5-ﬂuorouracil were treated at concentrations of 10 μM, 0.15 μM and
10 μM, and herbal dietary components, namely ginsenoside 20(S)-Rg3, curcumin and luteolin were
also treated at 10 μM, 20 μM and 50 μM, respectively.graphical work ﬂow of comprehensive proteomic analysis of colorectal cancer cells.
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The PBS-washed pellet of trypsinized cells were lysed with radioimmunoprecipitation (RIPA) buffer
containing 50mM Tris (pH 8.0), 150 mM NaCl, 1.0% (v/v) Triton X-100, 0.5% (w/v) deoxycholate and 1
protease inhibitor. 50 μg of denatured protein with sample buffer containing 300 mM Tris–HCl, 0.01% (w/v)
bromophenol blue, 15% (v/v) gycerol, 6% (w/v) SDS and 1% (v/v) β-mercaptoethanol were separated on 10%
Bis–Tris NuPAGE gels. Gels were stained using 0.04% (w/v) Coomassie brilliant blue G in 3.5% (v/v) perchloric
acid for 15 min and then destained using deionized water with several changes overnight. Each gel lanewas
cut into 20 slices, which were chopped into small pieces. Gel pieces were destained with 50% (v/v)
acetonitrile (ACN) containing 25 mM ammonium bicarbonate several times, and then were dehydrated in
100% ACN. After being dried in a Centrivap (Labconco, Kansas City, MO, USA), gel pieces were rehydrated in
50 mM ammonium bicarbonate containing 12.5 ng/μL trypsin, and then incubated at 37 1C overnight.
Peptides were extracted by adding 100 μL 50% (v/v) ACN containing 5% (v/v) formic acid and incubated at
room temperature for 30 min 3 times. The extracts were dried under vacuum and then were suspended in
5% (v/v) ACN containing 3% (v/v) formic acid to be subjected to LC–MS/MS.
1.3. Nano-LC and mass spectrometry analysis
The LC–MS/MS system used consisted of an LTQ/Orbitrap-XL mass spectrometer (Thermo Scientiﬁc,
Rockford, IL, USA) equipped with a NanoAcquity UPLC system (Waters, Milford, MA, USA). Peptides were
separated on a reversed phase analytical column (Nanoacquity BEH C18, 1.7 μm, 150 mm, Waters,
Milford, MA, USA) combined with trap column (NanoAcquity, Waters, Milford, MA, USA). Good
chromatographic separation was observed with a 75 min linear gradient consisting of mobile phases
solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in ACN) where the gradient was
from 5% B at 0 min to 40% B at 65 min. MS spectra were acquired by data dependent scans consisting of
MS/MS scans of the eight most intense ions from the full MS scan with dynamic exclusion of 30 s.
1.4. Database search and data compiling
The Human International Protein Index (IPI) v3.72 FASTA database (86,392 entries) was used within the
Bioworks software v.3.3.1 sp1 applying the SEQUEST search algorithm (SRF v.5). Search parameters were as
follows: parent mass tolerance of 10 ppm, fragment mass tolerance of 0.5 Da (monoisotopic), variable
modiﬁcation on methionine of 16 Da (oxidation) and maximum missed cleavage of 2 sites assuming the
digestion enzyme trypsin. Search results were compiled using Scaffold software v4.0.5 (Proteome Software,
Portland, OR, USA) which provided spectral counts for data comparison under the ﬁlter criteria of 2 peptides
minimum: XCorr scores of greater than 1.9, 2.3, 3.4 for singly, doubly and triply charged peptides, deltaCn
scores of greater than 0.10. Spectral counts from duplicate analysis were compared using the Power Law
Global Error Model (PLGEM) in order to identify the signiﬁcance of the protein changes [2].
Appendix A. Supporting information
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2014.10.005.
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